HC Wainwright Research Analysts Cut Earnings Estimates for Talaris Therapeutics, Inc.

TALSDelisted Stock  USD 2.98  0.10  3.25%   
Slightly above 61% of Talaris Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Talaris Therapeutics suggests that many traders are alarmed regarding Talaris Therapeutics' prospects. Talaris Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Talaris Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Talaris Therapeutics, Inc. HC Wainwright reduced their Q4 2022 earnings per share estimates for shares of Talaris Therapeutics in a research note issued on Monday, January 30th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn per share for the quarter, down from their prior

Read at thelincolnianonline.com
news
  

Talaris Therapeutics Fundamental Analysis

We analyze Talaris Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Talaris Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Talaris Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Z Score

Z Score Comparative Analysis

Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..

Talaris Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Talaris Therapeutics stock to make a market-neutral strategy. Peer analysis of Talaris Therapeutics could also be used in its relative valuation, which is a method of valuing Talaris Therapeutics by comparing valuation metrics with similar companies.

Peers

Talaris Therapeutics Related Equities

CGEMCullinan Oncology   5.94   
0%
100.0%
ACETAdicet Bio   5.81   
0%
97.0%
TILInstil Bio   2.64   
0%
44.0%
NXTCNextCure   2.11   
0%
35.0%
ACHLAchilles Therapeutics   1.03   
0%
17.0%
EWTXEdgewise Therapeutics   0.06   
1.0%
0%
NUVBNuvation Bio   0.37   
6.0%
0%
CTMXCytomX Therapeutics   0.91   
15.0%
0%
OVIDOvid Therapeutics   1.96   
32.0%
0%
VORVor Biopharma   2.25   
37.0%
0%
ASMBAssembly Biosciences   3.80   
63.0%
0%
SPROSpero Therapeutics   4.00   
67.0%
0%
CNTBConnect Biopharma   4.04   
68.0%
0%
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Other Consideration for investing in Talaris Stock

If you are still planning to invest in Talaris Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talaris Therapeutics' history and understand the potential risks before investing.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format